BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Daewoong Pharmaceutical Seeks Approval for Fexuprazan in China's Anti-Ulcer Drug Market

Daewoong Pharmaceutical's domestically produced drug no. 34 Fexuprazan, a newly developed one for the treatment of gastroesophageal reflux disease (GERD), ...

July 31, 2023 | News

Transcenta's Anti-sclerostin Antibody TST002 Approved for Phase II Trial in China for Reduced Bone Density Patients

This study aims to evaluate the safety, tolerability, and pharmacokinetics of TST002(Blosozumab) after single and multiple intravenous administrations in p...

July 31, 2023 | News

MSD and Moderna Launch Phase 3 Study for Melanoma Treatment

“As we continue our efforts to advance novel treatment options for patients with high-risk Stage IIB-IV melanoma, the initiation of the V940-001 Phas...

July 28, 2023 | News

GC Genome Enables Prognosis Prediction and Targeted Treatment in Breast Cancer

''We can gain vital insights into patient prognosis and make informed decisions regarding the most effective treatment strategies through ctDNA CNA...

July 27, 2023 | News

Hummingbird Bioscience Advances HMBD-001 Phase IB Trials in Australia, Partners with Omico for Faster Clinical Development

Hummingbird Bioscience has initiated two clinical trials in Australia evaluating HMBD-001 in patients with squamous non-small cell lung ca...

July 27, 2023 | News

BioMap unveils a “Life Science Leaderboard” to compare AI models

Highlights: New AI leaderboard provides comparison of 25+ of the most important, representative and cutting-edge tasks across six distinct...

July 26, 2023 | News

HaemaLogiX, Peter MacCallum Cancer Centre Announce Myeloma CAR-T Trial Agreement

HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX's ...

July 26, 2023 | News

Clarity reaches 50% recruitment milestone for Phase II SABRE prostate cancer trial

SABRE (Copper-64 SAR-Bombesin in Biochemical Recurrence of prostate cancer) is a Phase II Positron Emission Tomography (PET) imaging tr...

July 25, 2023 | News

China's Mabwell Announces NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND

B7-H3 is a member of the B7 ligand family and is overexpressed in most cancer types but expressed at a low level in normal tissues. In malignant tissues, B...

July 24, 2023 | News

Insilico Medicine Nominates Preclinical Candidate for ISM001-055, First Generative AI IPF Drug

Insilico Medicine merges nebulizer device with AI-driven drug discovery; Potential advantages for the inhalation solution include a smaller effe...

July 24, 2023 | News

AstraZeneca's Saphnelo Now Available in Malaysia for Adult Autoantibody-Positive SLE

SLE is a chronic and complex autoimmune condition that can affect any organ, and patients often experience inadequate disease control, long-term organ dama...

July 21, 2023 | News

US FDA Grants Orphan Drug Designation to SN Bioscience's 'SNB-101' for Small Cell Lung Cancer

SNB-101 showed excellent efficacy in animal small cell lung cancer models, and based on this, it has been designated as an orphan drug by the US FDA after ...

July 21, 2023 | News

Lynk Pharmaceuticals Doses First Atopic Dermatitis Patient with LNK01004 in Phase Ib Study

The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of LNK01004 ointment in Chinese patie...

July 21, 2023 | News

BioCity Initiates Phase 1 Trial with CDH3-Targeting ADC BC3195, First Patient Dosed

The study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of BC3195 in patients with locally advanced or metastatic solid ...

July 20, 2023 | News

Stay Connected